U.S. markets closed

Emergent BioSolutions Inc. (EBS)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
29.39-1.11 (-3.64%)
At close: 04:00PM EDT
29.50 +0.11 (+0.37%)
After hours: 06:42PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Intermediate-term KST

Intermediate-term KST

Previous Close30.50
Bid28.85 x 900
Ask30.00 x 800
Day's Range29.05 - 30.36
52 Week Range26.85 - 65.09
Avg. Volume766,230
Market Cap1.465B
Beta (5Y Monthly)0.97
PE Ratio (TTM)17.19
EPS (TTM)1.71
Earnings DateNov 02, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est41.21
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
117% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for EBS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Emergent Biosolutions, Inc.
    Analyst Report: Emergent BioSolutions IncEmergent BioSolutions makes vaccines and other products intended to protect civilian and military populations from emerging infectious diseases and chemical, biological or nuclear attacks. The company generates its revenue from product sales of its smallpox vaccine (ACAM2000), its anthrax vaccines (BioThrax and AV7909), and its Narcan nasal spray (a treatment for opioid overdoses), as well as from contract development and manufacturing services and contracts and grants. The USG is the company's primary customer, and provides EBS with significant product development funding. EBS shares are a component of the S&P 400 Index. The company has approximately 2,400 employees.
    Fair Value
    Economic Moat
    29 days agoArgus Research
View more
  • Benzinga

    FDA Issues Warning Letter For Emergent Bio's Manufacturing Facility

    The FDA issued a warning letter to Emergent BioSolutions Inc (NYSE: EBS), citing certain deficiencies at the company's troubled manufacturing facility in Baltimore, Maryland. The FDA pointed to equipment cleaning and maintenance deficiencies to prevent drug product contamination. Reuters reported that the agency also recommended that the company review its quality control process. Related: Emergent Bio Says Johnson & Johnson Breached COVID-19 Vaccine Contract. Emergent had said the FDA had last

  • Reuters

    Emergent receives FDA warning letter over quality control issues

    The FDA pointed to deficiencies in cleaning and maintenance of equipment to prevent contamination of drug product and also recommended the company review its quality control process, Emergent said. Earlier in August, Emergent had said the FDA had last inspected its facility at Camden in February and was waiting for the agency's feedback.

  • GlobeNewswire

    Emergent BioSolutions to Participate in Investor Conferences

    GAITHERSBURG, Md., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following investor conferences: 12th Annual Midwest IDEAS Investor ConferenceChicago, ILAugust 24, 2022 – presentation scheduled at 5:15 PM central time Wells Fargo 2022 Healthcare ConferenceBoston, MASeptember 8, 2022 – fireside chat scheduled at 9:10 AM easter